STOCK TITAN

Akari Therapeutics Plc - AKTX STOCK NEWS

Welcome to our dedicated news page for Akari Therapeutics Plc (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akari Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akari Therapeutics Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
conferences
Akari Therapeutics Plc

Nasdaq:AKTX

AKTX Rankings

AKTX Stock Data

9.16M
9.56B
17.91%
1.61%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AKTX

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.